je.st
news
Home
› Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation Of A Phase 1 Clinical Trial Of Anticancer Drug MRX34
Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation Of A Phase 1 Clinical Trial Of Anticancer Drug MRX34
2013-06-05 06:56:06| drugdiscoveryonline News Articles
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer
Tags: reported
trial
drug
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||